{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Cellular (T-cell) response was not analysed as data only available for few patients.","groups":[{"description":"Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.","id":"OG000","title":"NY-ESO 1 Group"}],"populationDescription":"As study development was stopped earlier, and decision was taken not to perform further testing on biological samples already collected, except if a scientific rationale remained relevant, Cellular (T-cell) response was not analysed as data only available for few patients.","reportingStatus":"POSTED","timeFrame":"Before treatment (PRE), at 4 (W4), 8 (W8), 10 (W10), 12 (W12), 29 (W29), 51 (W51), 75 (W75), 99 (W99), 123 (W123) weeks of treatment and at the concluding visit, i.e. at Month 49 (POST)","title":"Cell Mediated Immune Response for Anti-NY-ESO-1 Antibodies (T-cell)","type":"SECONDARY"}